Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Refardt J
Authors: Refardt J, Zandee W, Brabander T, Feelders R, Franssen G,
Keywords: somatostatin receptor type 2, outcome, propensity score analysis, survival,
Introduction: A mesenteric mass surrounded by fibrosis is a hallmark feature of small intestinal neuroendocrine tumors (SI-NETs) that can induce severe abdominal complications. To improve clinical outcome, there is a need for personalized treatment strategies based on accurate prediction of development of abdominal complications.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Blazevic A
Authors: Blazevic A, Starman M, Brabander T, Hofland J, Franssen G,
Keywords: Small-intestinal neuroendocrine tumors, mesenteric mass, mesenteric fibrosis, radiomics, CT scan,
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is effective in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: van der Zwan W
Authors: Van der Zwan W, Brabander T, Kam B, Teunissen J, Krenning E,
Keywords: Salvage, PRRT, Re-treatment, GEP-NET, Safety, Efficacy, 177Lu-DOTATATE,
Introduction: PRRT with 177Lu-DOTATATE (LuTate) is an effective treatment option in patients with metastatic or inoperable GEP-NETs.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: van der Zwan W
Authors: Van der Zwan W, Wyld D, Brabander T, Teunissen J, Kam B,
Keywords: PRRT, 177Lu-DOTATATE, Capecitabine, Xeloda, PFS, OS, Toxicity, GEP-NET, RCT, Randomized,
Introduction: PPRT with [177Lu-DOTA0,Tyr3]octreotate (177Lu-DOTATATE) is a treatment with good results in patients with metastatic GEPNETs
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Brabander T, Van der Zwan W, Teunissen J, Kam B, de Herder W,
Keywords: 177Lu-DOTATATE, PRRT, response evaluation, toxicity,